Trial | NCT00346957  Report issue

Title

A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Indication/Condition

    AMD

  • Intervention/Treatment

    Anecortave ...

  • Study Participants

    128
The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.
Study Started
Apr 30
1999
Primary Completion
Apr 30
2003
Study Completion
Apr 30
2003
Last Update
Mar 06
2012
Estimate

Drug Anecortave acetate 30 mg

0.5ml administered onto the sclera once every six months for 24 months

Drug Anecortave Acetate 15 mg

0.5ml administered onto the sclera once every six months for 24 months

Drug Anecortave Acetate 3 mg

0.5ml administered onto the sclera once every six months for 24 months

Other Anecortave Acetate Vehicle

0.5ml administered onto the sclera once every six months for 24 months

Anecortave Acetate 30 Experimental

Anecortave Acetate 15 Experimental

Anecortave Acetate 3 Experimental

Anecortave Acetate Vehicle Placebo Comparator

Criteria 

Inclusion Criteria:

Ages 50 years and over
Other protocol-defined inclusion and exclusion criteria may apply.
No Results Posted